Entry

D10446                      Drug

Name

Margetuximab (USAN);
Margetuximab-cmkb;
Margenza (TN)

Product

MARGENZA (MacroGenics)

Formula

C6484H10010N1726O2024S42

Exact mass

145782.1685

Mol weight

145871.938

Sequence

(Heavy chain)
QVQLQQSGPE LVKPGASLKL SCTASGFNIK DTYIHWVKQR PEQGLEWIGR IYPTNGYTRY
DPKFQDKATI TADTSSNTAY LQVSRLTSED TAVYYCSRWG GDGFYAMDYW GQGASVTVSS
ASTKGPSVFP LAPSSKSTSG GTAALGCLVK DYFPEPVTVS WNSGALTSGV HTFPAVLQSS
GLYSLSSVVT VPSSSLGTQT YICNVNHKPS NTKVDKRVEP KSCDKTHTCP PCPAPELVGG
PSVFLLPPKP KDTLMISRTP EVTCVVVDVS HEDPEVKFNW YVDGVEVHNA KTKPPEEQYN
STLRVVSVLT VLHQDWLNGK EYKCKVSNKA LPAPIEKTIS KAKGQPREPQ VYTLPPSRDE
LTKNQVSLTC LVKGFYPSDI AVEWESNGQP ENNYKTTPLV LDSDGSFFLY SKLTVDKSRW
QQGNVFSCSV MHEALHNHYT QKSLSLSPGK
(Light chain)
DIVMTQSHKF MSTSVGDRVS ITCKASQDVN TAVAWYQQKP GHSPKLLIYS ASFRYTGVPD
RFTGSRSGTD FTFTISSVQA EDLAVYYCQQ HYTTPPTFGG GTKVEIKRTV AAPSVFIFPP
SDEQLKSGTA SVVCLLNNFY PREAKVQWKV DNALQSGNSQ ESVTEQDSKD STYSLSSTLT
LSKADYEKHK VYACEVTHQG LSSPVTKSFN RGEC
(Disulfide bridge: H22-H96, H'22-H'96, L23-L88, L'23-L'88, L134-L194, L'134-L'194, H147-H203, H'147-H'203, H223-L214, H'223-L'214, H229-H'229, H232-H'232, H264-H324, H'264-H'324, H370-H428, H'370-H'428; Glycosylation site: Asn-H300, Asn-H'300)

Type

Peptide

Class

Antineoplastic
DG01918  Tyrosine kinase inhibitor
  DG01917  Receptor tyrosine kinase inhibitor
   DG03158  HER2 inhibitor

Remark

Product:

D10446<US>

Efficacy

Antineoplastic, Anti-HER2 antibody

Disease

Breast cancer (HER2 positive) [DS:H00031]

Comment

Monoclonal antibody

Target

ERBB2* (HER2, CD340) [HSA_VAR:2064v1] [HSA:2064] [KO:K05083]

Pathway

hsa04012

ErbB signaling pathway

hsa05200

Pathways in cancer

hsa05224

Breast cancer

Interaction

Brite

USP drug classification [BR:br08302]
Antineoplastics
  Monoclonal Antibody/Antibody-Drug Conjugate
   Margetuximab
    D10446  Margetuximab (USAN)
Drug groups [BR:br08330]
Antineoplastic
  DG01918  Tyrosine kinase inhibitor
   DG01917  Receptor tyrosine kinase inhibitor
    DG03158  HER2 inhibitor
     D10446  Margetuximab
Drug classes [BR:br08332]
Antineoplastic
  DG03158  HER2 inhibitor
   D10446  Margetuximab
Target-based classification of drugs [BR:br08310]
Protein kinases
  Receptor tyrosine kinases (RTK)
   EGFR family
    ERBB2* (HER2, CD340) [HSA_VAR:2064v1]
     D10446  Margetuximab (USAN) <US>
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
  D10446
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
  D10446
Pharmacogenomic biomarkers [br08341.html]
Somatic variations in targeted cancer therapies
  D10446

Other DBs

CAS:	1350624-75-7

PubChem:

172232539